Literature DB >> 33322204

Discordance between Primary Breast Cancer and Ipsilateral Breast Cancer Tumor Recurrence as a Function of Distance.

Sebastian M Jud1, Reinhard Hatko2, Julius Emons1, Bianca Lauterbach1, Carolin C Hack1, Caroline Preuß1, Werner Adler3, Matthias W Beckmann1, Felix Heindl1.   

Abstract

BACKGROUND: Risk factors for ipsilateral breast cancer tumor recurrence (IBTR) are well established and include grading, nodal status, and receptor status. Little is known about the influence of the local distance between the primary tumor and recurrences on changes in tumor characteristics and prognosis.
METHODS: In a retrospective setting, we analyzed primary breast cancers and their recurrences. Localizations of primary and recurrent breast cancer were recorded to calculate the relative distance in pixels. Analysis was performed regarding tumor characteristics, relative distance between both, and their impact on breast cancer prognosis.
RESULTS: In a cohort of 142 patients with ipsilateral recurrence, no statistically significant difference could be shown in the change in tumor characteristics depending on distance. Progesterone receptor (PR) and estrogene receptor (ER) status changed in 22.7% and 14.9% of cases, respectively. human epidermal growth factor receptor 2 (ERBB2, HER2) status changed in 18.3% of cases. Survival was in accordance with the literature, with luminal-A-like tumors as best and triple negative breast cancers (TNBC) as worst prognosis. With a threshold of 162 pixels, the survival was significantly better in the group with shorter distance.
CONCLUSION: Change in tumor characteristics from primary breast cancer to recurrence occurs more often in PR than ER. In contrast to other work, in this dataset, recurrences with a larger distance to the primary tumor had a worse prognosis in univariate analysis. A Cox model might indicate the possibility that this influence is independent of other risk factors.

Entities:  

Keywords:  breast cancer; ipsilateral recurrence; prognosis; tumor characteristics

Year:  2020        PMID: 33322204      PMCID: PMC7764724          DOI: 10.3390/jcm9124033

Source DB:  PubMed          Journal:  J Clin Med        ISSN: 2077-0383            Impact factor:   4.241


  23 in total

Review 1.  Locoregional recurrence after breast cancer surgery: a systematic review by receptor phenotype.

Authors:  Aoife J Lowery; Malcolm R Kell; Ronan W Glynn; Michael J Kerin; Karl J Sweeney
Journal:  Breast Cancer Res Treat       Date:  2011-12-07       Impact factor: 4.872

2.  Change in estrogen receptor, HER2, and Ki-67 status between primary breast cancer and ipsilateral breast cancer tumor recurrence.

Authors:  Y Okumura; R Nishimura; K Nakatsukasa; A Yoshida; N Masuda; M Tanabe; T Shien; S Tanaka; N Arima; Y Komoike; T Taguchi; T Iwase; H Inaji; M Ishitobi
Journal:  Eur J Surg Oncol       Date:  2015-02-07       Impact factor: 4.424

3.  Ipsilateral breast tumor recurrence (IBTR) after breast-conserving treatment for early breast cancer: risk factors and impact on distant metastases.

Authors:  Yoshifumi Komoike; Futoshi Akiyama; Yuichi Iino; Tadashi Ikeda; Sadako Akashi-Tanaka; Shozo Ohsumi; Mikihiro Kusama; Muneaki Sano; Eisei Shin; Kimito Suemasu; Hiroshi Sonoo; Tetsuya Taguchi; Tsunehiro Nishi; Reiki Nishimura; Shunsuke Haga; Keiichi Mise; Takayuki Kinoshita; Shigeru Murakami; Masataka Yoshimoto; Hideaki Tsukuma; Hideo Inaji
Journal:  Cancer       Date:  2006-01-01       Impact factor: 6.860

4.  Locoregional failure 10 years after mastectomy and adjuvant chemotherapy with or without tamoxifen without irradiation: experience of the Eastern Cooperative Oncology Group.

Authors:  A Recht; R Gray; N E Davidson; B L Fowble; L J Solin; F J Cummings; G Falkson; H C Falkson; S G Taylor; D C Tormey
Journal:  J Clin Oncol       Date:  1999-06       Impact factor: 44.544

5.  Locoregional recurrence patterns after mastectomy and doxorubicin-based chemotherapy: implications for postoperative irradiation.

Authors:  A Katz; E A Strom; T A Buchholz; H D Thames; C D Smith; A Jhingran; G Hortobagyi; A U Buzdar; R Theriault; S E Singletary; M D McNeese
Journal:  J Clin Oncol       Date:  2000-08       Impact factor: 44.544

6.  Risk factors for locoregional recurrence among breast cancer patients: results from International Breast Cancer Study Group Trials I through VII.

Authors:  A Wallgren; M Bonetti; R D Gelber; A Goldhirsch; M Castiglione-Gertsch; S B Holmberg; J Lindtner; B Thürlimann; M Fey; I D Werner; J F Forbes; K Price; A S Coates; J Collins
Journal:  J Clin Oncol       Date:  2003-04-01       Impact factor: 44.544

7.  Clinicopathologic factors of the recurrent tumor predict outcome in patients with ipsilateral breast tumor recurrence.

Authors:  Valerie Panet-Raymond; Pauline T Truong; Cheryl Alexander; Mary Lesperance; Rachel E McDonald; Peter H Watson
Journal:  Cancer       Date:  2010-11-29       Impact factor: 6.860

8.  Chemotherapy for isolated locoregional recurrence of breast cancer (CALOR): a randomised trial.

Authors:  Stefan Aebi; Shari Gelber; Stewart J Anderson; István Láng; André Robidoux; Miguel Martín; Johan W R Nortier; Alexander H G Paterson; Mothaffar F Rimawi; José Manuel Baena Cañada; Beat Thürlimann; Elizabeth Murray; Eleftherios P Mamounas; Charles E Geyer; Karen N Price; Alan S Coates; Richard D Gelber; Priya Rastogi; Norman Wolmark; Irene L Wapnir
Journal:  Lancet Oncol       Date:  2014-01-16       Impact factor: 41.316

9.  Local recurrences and distant metastases after breast-conserving surgery and radiation therapy for early breast cancer.

Authors:  E Touboul; L Buffat; Y Belkacémi; J P Lefranc; S Uzan; P Lhuillier; C Faivre; J Huart; J P Lotz; M Antoine; F Pène; J Blondon; V Izrael; A Laugier; M Schlienger; M Housset
Journal:  Int J Radiat Oncol Biol Phys       Date:  1999-01-01       Impact factor: 7.038

10.  Interdisciplinary Screening, Diagnosis, Therapy and Follow-up of Breast Cancer. Guideline of the DGGG and the DKG (S3-Level, AWMF Registry Number 032/045OL, December 2017) - Part 2 with Recommendations for the Therapy of Primary, Recurrent and Advanced Breast Cancer.

Authors:  Achim Wöckel; Jasmin Festl; Tanja Stüber; Katharina Brust; Mathias Krockenberger; Peter U Heuschmann; Steffi Jírů-Hillmann; Ute-Susann Albert; Wilfried Budach; Markus Follmann; Wolfgang Janni; Ina Kopp; Rolf Kreienberg; Thorsten Kühn; Thomas Langer; Monika Nothacker; Anton Scharl; Ingrid Schreer; Hartmut Link; Jutta Engel; Tanja Fehm; Joachim Weis; Anja Welt; Anke Steckelberg; Petra Feyer; Klaus König; Andrea Hahne; Traudl Baumgartner; Hans H Kreipe; Wolfram Trudo Knoefel; Michael Denkinger; Sara Brucker; Diana Lüftner; Christian Kubisch; Christina Gerlach; Annette Lebeau; Friederike Siedentopf; Cordula Petersen; Hans Helge Bartsch; Rüdiger Schulz-Wendtland; Markus Hahn; Volker Hanf; Markus Müller-Schimpfle; Ulla Henscher; Renza Roncarati; Alexander Katalinic; Christoph Heitmann; Christoph Honegger; Kerstin Paradies; Vesna Bjelic-Radisic; Friedrich Degenhardt; Frederik Wenz; Oliver Rick; Dieter Hölzel; Matthias Zaiss; Gudrun Kemper; Volker Budach; Carsten Denkert; Bernd Gerber; Hans Tesch; Susanne Hirsmüller; Hans-Peter Sinn; Jürgen Dunst; Karsten Münstedt; Ulrich Bick; Eva Fallenberg; Reina Tholen; Roswita Hung; Freerk Baumann; Matthias W Beckmann; Jens Blohmer; Peter Fasching; Michael P Lux; Nadia Harbeck; Peyman Hadji; Hans Hauner; Sylvia Heywang-Köbrunner; Jens Huober; Jutta Hübner; Christian Jackisch; Sibylle Loibl; Hans-Jürgen Lück; Gunter von Minckwitz; Volker Möbus; Volkmar Müller; Ute Nöthlings; Marcus Schmidt; Rita Schmutzler; Andreas Schneeweiss; Florian Schütz; Elmar Stickeler; Christoph Thomssen; Michael Untch; Simone Wesselmann; Arno Bücker; Andreas Buck; Stephanie Stangl
Journal:  Geburtshilfe Frauenheilkd       Date:  2018-11-26       Impact factor: 2.915

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.